Literature DB >> 9440752

Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.

E W Steyerberg1, A Gerl, S D Fossá, D T Sleijfer, R de Wit, W J Kirkels, N Schmeller, C Clemm, J D Habbema, H J Keizer.   

Abstract

PURPOSE: To validate predictions of the histology (necrosis, mature teratoma, or cancer) of residual retroperitoneal masses in patients treated with chemotherapy for metastatic nonseminomatous testicular germ cell tumor. PATIENTS AND METHODS: We studied 172 testicular cancer patients who underwent resection while tumor markers were normal. Predictive characteristics for the residual histology were registered, including the presence of teratoma elements in the primary tumor, the prechemotherapy level of tumor markers (alpha-fetaprotein [AFP], human chorionic gonadotropin [HCG], lactate dehydrogenase [LDH]), the size of the residual mass, and the percentage of shrinkage in mass diameter. We calculated the predicted probability of necrosis and the ratio of cancer and mature teratoma with previously published logistic regression formulas.
RESULTS: The distribution of the residual histology was necrosis in 77 (45%), mature teratoma in 72 (42%), and cancer in 23 (13%). Necrosis could be well distinguished from other tissue, with an area under the receiver operating characteristic (ROC) curve of 82%. No tumor was found in 15 patients with a predicted probability of necrosis over 90%. The predicted probabilities corresponded reliably with the observed probabilities (goodness-of-fit tests, P > .20), although a somewhat higher probability of necrosis was observed in patients treated with chemotherapy containing etoposide. Conversely, cancer could not reliably be predicted or adequately discriminated from mature teratoma.
CONCLUSION: The predicted probabilities of necrosis have adequate reliability and discriminative power. These predictions may validly support the decision-making process regarding the need and extent of retroperitoneal lymph node dissection.

Entities:  

Mesh:

Year:  1998        PMID: 9440752     DOI: 10.1200/JCO.1998.16.1.269

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  Assessing the discriminative ability of risk models for more than two outcome categories.

Authors:  Ben Van Calster; Yvonne Vergouwe; Caspar W N Looman; Vanya Van Belle; Dirk Timmerman; Ewout W Steyerberg
Journal:  Eur J Epidemiol       Date:  2012-10-07       Impact factor: 8.082

2.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

3.  Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.

Authors:  S Considine; R Heaney; R Conroy; J A Thornhill
Journal:  Ir J Med Sci       Date:  2015-12-21       Impact factor: 1.568

4.  [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].

Authors:  J Müller; A J Schrader; F Jentzmik; M Schrader
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

Review 5.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

6.  Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.

Authors:  Hugh J Lavery; Robert R Bahnson; David S Sharp; Kamal S Pohar
Journal:  Ther Adv Urol       Date:  2009-10

7.  Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Authors:  Solomon L Woldu; Joseph A Moore; Bo Ci; Yuval Freifeld; Timothy N Clinton; Ahmet M Aydin; Nirmish Singla; Krabbe Laura-Maria; Ryan C Hutchinson; James F Amatruda; Arthur Sagalowsky; Yair Lotan; Yull Arriaga; Vitaly Margulis; Yang Xie; Aditya Bagrodia
Journal:  Eur Urol Oncol       Date:  2018-06-06

Review 8.  Update on epidemiologic considerations and treatment trends in testicular cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2018-09       Impact factor: 2.309

Review 9.  The role of positron emission tomography in germ cell cancer.

Authors:  Maria De Santis; Jörg Pont
Journal:  World J Urol       Date:  2004-03-16       Impact factor: 4.226

Review 10.  [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].

Authors:  P Schriefer; M Hartmann; K Oechsle; C P Meyer; S Klutmann; M Fisch; C Bokemeyer; C Oing
Journal:  Urologe A       Date:  2019-04       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.